Immunotherapy plus chemo before surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called AK104, which helps the immune system fight cancer, combined with chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this combination can shrink tumors enough to make surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 74 years old.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV).
- You have not had any prior treatment for ovarian cancer, such as chemotherapy, radiation, or surgery (except for biopsy).
- You have at least one tumor that can be measured on a scan.
- You are in generally good health, with a performance status of 0 to 2 (able to do light activity).
- You are not pregnant or breastfeeding, and if you can have children, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests a new drug called AK112 combined with chemotherapy or another drug (olaparib) for people with ovarian cancer that came back more than 6 months after platinum treatment. The goal is to see if these combinations work better than current options.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a combination of two immunotherapy drugs with chemotherapy, with or without a targeted therapy pill, given before surgery for advanced ovarian cancer. It aims to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.